Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | KDM5A | P29375 | 3/20 | 0.47 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.47 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.47 |
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10633859 | 0.88 | HPGD (0.54) | HPGDALDH1A1EPHX2EPHX1KDM5A | |
| SCHEMBL10633798 | 0.88 | HPGD (0.54) | HPGDALDH1A1EPHX2EPHX1KDM5A | |
| SCHEMBL9071922 | 0.88 | EPHX2 (0.57) | HPGDALDH1A1EPHX2EPHX1KDM5A | |
| SCHEMBL21882669 | 0.87 | KDM5A (0.50) | HPGDALDH1A1EPHX2EPHX1HDAC3 | |
| SCHEMBL25911804 | 0.87 | KDM5A (0.50) | HPGDALDH1A1EPHX2EPHX1HDAC3 | |
| SCHEMBL7286378 | 0.87 | HDAC3 (0.51) | HPGDALDH1A1EPHX2EPHX1HDAC3 | |
| SCHEMBL24882522 | 0.85 | KDM5A (0.52) | HPGDALDH1A1EPHX2EPHX1HDAC3 | |
| SCHEMBL8847821 | 0.83 | ALDH1A1 (0.56) | HPGDALDH1A1EPHX2EPHX1HDAC3 | |
| SCHEMBL20016275 | 0.83 | ALDH1A1 (0.58) | HPGDALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL8847507 | 0.82 | CASP2 (0.56) | HPGDALDH1A1EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220133685-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR HOLDINGS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-11246852-B2 | Fast-acting plant-based medicinal compounds and nutritional supplements | RECEPTOR HOLDINGS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210393575-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | RECEPTOR HOLDINGS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20200101034-A1 | RAPID AND CONTROLLED DELIVERY OF COMPOSITIONS WITH RESTORED ENTOURAGE EFFECTS | RECEPTOR HOLDINGS, INC. (US) | 2020-04-02 | — | — | US | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| US-9370492-B2 | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers | EMISPHERE TECHNOLOGIES, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9370492-B2 | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers | EMISPHERE TECHNOLOGIES, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20090281064-A1 | SOLID PHARMACEUTICAL DOSAGE FORMS COMPRISING BISPHOSPHONATES AND MODIFIED AMINO ACID CARRIERS | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281064-A1 | SOLID PHARMACEUTICAL DOSAGE FORMS COMPRISING BISPHOSPHONATES AND MODIFIED AMINO ACID CARRIERS | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-7417022-B2 | Compounds and compositions for delivering active agents | MHR INSTITUTIONAL PARTNERS IIA LP (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417022-B2 | Compounds and compositions for delivering active agents | MHR INSTITUTIONAL PARTNERS IIA LP (US) | 2008-08-26 | — | — | US | disclosed |
| WO-2007093226-A1 | ORAL IBANDRONATE FORMULATIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| EP-1792624-A1 | Modified amino acids and compositions comprising them for delivering active agents | Emisphere Technologies, Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| US-20070049557-A1 | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers | EMISPHERE TECHNOLOGIES, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049557-A1 | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers | EMISPHERE TECHNOLOGIES, INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281064-A1 | SOLID PHARMACEUTICAL DOSAGE FORMS COMPRISING BISPHOSPHONATES AND MODIFIED AMINO ACID CARRIERS | SLC1A5, SLC7A5, SLC7A1 | HPGD 1445/4885ALDH1A1 4142/4885EPHX2 4340/4885 |
| US-11246852-B2 | Fast-acting plant-based medicinal compounds and nutritional supplements | SLC1A5, SLC43A1, SLC27A2 | HPGD 1211/4885ALDH1A1 3578/4885EPHX2 4247/4885 |
| US-20070049557-A1 | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers | SLC1A5, SLC7A5, SLC7A1 | HPGD 1446/4885ALDH1A1 4141/4885EPHX2 4351/4885 |
| US-20200101034-A1 | RAPID AND CONTROLLED DELIVERY OF COMPOSITIONS WITH RESTORED ENTOURAGE EFFECTS | FABP2, ASS1, AADAT | HPGD 2140/4885ALDH1A1 2656/4885EPHX2 2470/4885 |
| US-20210393575-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | FAAH, CNR2, FABP2 | HPGD 2239/4885ALDH1A1 3661/4885EPHX2 1872/4885 |
| US-20220133685-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SLC1A5, SLC43A1, SLC27A2 | HPGD 1211/4885ALDH1A1 3578/4885EPHX2 4247/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | HPGD 1489/4885ALDH1A1 3725/4885EPHX2 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.